不同表面活性剂对帕克利塔克塞尔/HPMC-AS无形固体分散剂口服生物可用性的影响
Chenzhao Zhang1, Siyi Mao1, Jinhua Yuan1
1School of Pharmacy, Minzu University of China, Beijing 100081, China.
Pharmaceutics
|November 27, 2025
概括
表面活性剂的选择显著影响无形固体分散 (ASD) 的性能. 兼容的表面活性剂通过改善溶解和保持无形稳定性来增强帕克利塔塞尔 (PTX) 的生物可用性,而不兼容的表面活性剂则会降低其.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 材料科学 材料科学 材料科学
背景情况:
- 表面活性剂是无形固体分散 (ASD) 中的关键辅助物质,用于增强药物溶解和生物可用性,特别是在水溶性较差的药物中.
- 不同表面活性剂对ASD表现的确切影响,包括溶解,生物可用性和体外-体内相关性 (IVIVC),尚未完全理解,阻碍了合理的ASD配方设计.
- 帕克利塔塞尔 (PTX) 是一种水溶性较差的药物,通常用基基甲基纤维素酸酸盐 (HPMC-AS) 作为ASD配制.
研究的目的:
- 研究六种不同的表面活性剂 (SLG,NaTC,SLS,TW80,P188,Brij-35) 对帕克利塔塞尔 (PTX) /HPMC-AS无形固体分散 (ASD) 的性能的影响.
- 阐明表面活性剂影响PTX溶解,超和,物理稳定性和体内生物可用性的机制.
- 建立药物-聚合物-表面活性剂相互作用,溶解行为和合理ASD设计的药物动力学结果之间的关系.
主要方法:
- 制备二元PTX/HPMC-AS和三元PTX/HPMC-AS/表面活性剂ASDs.
- 使用FT-IR和NMR光谱学评估药物-聚合物-表面活性剂相互作用.
- 综合溶解测试,包括可溶性,超和维持能力和相变分析.
- 在口服服用ASD配方后,对老鼠体内生物利用度的评估.
主要成果:
- 表面活性剂选择表明对PTX生物可用性的特定影响:SLG和P188由于不兼容性和弱相互作用而显示出最小的影响.
- 通过诱导药物结晶,TW80显著降低了生物可用性,从而损害了无形优势.
- NaTC,Brij-35和SLS通过促进药物溶解性,保持无形状态,并由于有利的药物-聚合物-表面活性剂兼容性维持超和,显著提高了生物可用性.
结论:
- 药物,聚合物和表面活性剂之间的兼容性是ASD溶解和生物可用性的基本决定因素.
- 表面活性剂的战略选择对于优化ASD生物可用性至关重要,其作用通过调节超和和固态稳定性来调节.
- 将分子相互作用分析与详细的溶解造型进行整合,包括超和动力学和沉相分析,对于高性能ASD的合理设计至关重要.
相关概念视频
Bioavailability Enhancement: Drug Solubility Enhancement
204
Body:Bioavailability is a critical factor in determining a drug's effectiveness. It refers to the proportion of a drug that enters the circulation when introduced into the body and is, as a result, able to have an active effect. Enhancing bioavailability is essential for drugs with poor solubility, as it can significantly impact their therapeutic efficacy. Various methods are employed to increase the solubility of drugs, thereby enhancing their bioavailability.Micronization and nanonization are...
204
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
481
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
481
Factors Influencing Drug Absorption: Pharmaceutical Parameters
383
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
383
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
3.0K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
3.0K
Factors Affecting Dissolution: Particle Size and Effective Surface Area
1.6K
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
1.6K
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
139
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
139


